{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:43Z","timestamp":1792685923744,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Dual antiplatelet therapy (DAPT) appears to be an effective treatment option for minor (nondisabling) acute ischemic stroke. This conclusion is based on trials that include both transient ischemic attack (TIA) and minor stroke; however, these 2 conditions may differ.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare DAPT regimens specifically for minor stroke.<\/jats:p><\/jats:sec>Data Sources<\/jats:title>PubMed was searched for randomized clinical trials published up to November 4, 2023. Search terms strategy included TIA<\/jats:italic>, transient ischemic attack<\/jats:italic>, minor stroke<\/jats:italic>, or moderate stroke<\/jats:italic>, with the filter randomized controlled trial<\/jats:italic>. Unpublished data on minor stroke were sourced from authors and\/or institutions.<\/jats:p><\/jats:sec>Study Selection<\/jats:title>Trials testing DAPT within the first 24 hours of a minor stroke (defined as a National Institutes of Health Stroke Scale score \u22645) were included by consensus. Of 1508 studies screened, 6 (0.3%) initially met inclusion criteria and were reviewed.<\/jats:p><\/jats:sec>Data Extraction and Synthesis<\/jats:title>The study was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines by multiple observers. Bayesian fixed-effect network meta-analysis was conducted. Secondary analysis performed for high-risk TIA alone.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Treatments were ranked using a probability measure called surface under the cumulative rank curve (SUCRA). The primary outcome was subsequent ischemic stroke at 90 days. Secondary outcomes included major hemorrhage, mortality, and hemorrhagic stroke. The number needed to treat (NNT) and number needed to harm (NNH) were obtained.<\/jats:p><\/jats:sec>Results<\/jats:title>Five trials were included that described 28\u202f148 patients, of whom 22\u202f203 (78.9%) had a minor stroke. Of these, 13\u202f995 (63.0%) were in DAPT groups and 8208 (37.0%) in aspirin (acetylsalicylic acid) groups. Aspirin and ticagrelor had a 94% probability of being the superior treatment for minor stroke (SUCRA, 0.94) for the primary outcome. Both aspirin and ticagrelor (NNT, 40; 95% CI, 31-64) and aspirin and clopidogrel (NNT, 58; 95% CI, 39-136) were superior to aspirin alone in the prevention of recurrent ischemic stroke at 90 days. Both treatments had higher rates of major hemorrhage than aspirin alone (NNH for aspirin and ticagrelor, 284; 95% CI, 108-1715 vs NNH for aspirin and clopidogrel, 330; 95% CI, 118-3430), but neither had increased risk of hemorrhagic stroke or death. For high-risk TIA, ticagrelor and aspirin had a 60% probability (SUCRA, 0.60) and clopidogrel and aspirin had a 40% probability (SUCRA 0.40) of being a superior treatment; neither was optimum, but both were superior to aspirin alone for the primary outcome.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>These findings suggest that DAPT with aspirin and ticagrelor has higher probability of being the superior treatment among patients with minor stroke when presence of CYP2C19<\/jats:italic> loss-of-function alleles has not been excluded. For patients with TIA, the superiority of aspirin and ticagrelor vs aspirin and clopidogrel was not demonstrated.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.11735","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T15:01:09Z","timestamp":1715871669000},"page":"e2411735","source":"Crossref","is-referenced-by-count":10,"title":["Comparison of Dual Antiplatelet Therapies for Minor, Nondisabling, Acute Ischemic Stroke: A Bayesian Network Meta-Analysis"],"prefix":"10.1001","volume":"7","author":[{"given":"Andy","family":"Lim","sequence":"first","affiliation":[{"name":"School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Emergency Medicine, Monash Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Division of Clinical Trials, Imaging, and Informatics, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia (SM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ly","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaloo","family":"Singhal","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Division of Clinical Trials, Imaging, and Informatics, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia (SM)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuesong","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Centre for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"},{"name":"China National Clinical Research Centre for Neurological Diseases, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Claiborne","family":"Johnston","sequence":"additional","affiliation":[{"name":"University of California, San Francisco"},{"name":"Harbor Health, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh G.","family":"Phan","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia"},{"name":"Department of Neurology, Division of Clinical Trials, Imaging, and Informatics, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia (SM)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"issue":"11","key":"zoi240417r1","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1161\/STROKEAHA.120.030898","article-title":"Reperfusion therapy frequency and outcomes in mild ischemic stroke in the United States.","volume":"51","author":"Saber","year":"2020","journal-title":"Stroke"},{"issue":"2","key":"zoi240417r2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.8496","article-title":"Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial.","volume":"320","author":"Khatri","year":"2018","journal-title":"JAMA"},{"issue":"24","key":"zoi240417r3","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1001\/jama.2023.7827","article-title":"Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial.","volume":"329","author":"Chen","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"zoi240417r4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi240417r5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi240417r6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA.","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi240417r7","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1161\/STROKEAHA.112.664060","article-title":"Monash transient ischemic attack triaging treatment: safety of a transient ischemic attack mechanism-based outpatient model of care.","volume":"43","author":"Sanders","year":"2012","journal-title":"Stroke"},{"issue":"5","key":"zoi240417r8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/STROKEAHA.114.008632","article-title":"Four-year follow-up of transient ischemic attacks, strokes, and mimics: a retrospective transient ischemic attack clinic cohort study.","volume":"46","author":"Dutta","year":"2015","journal-title":"Stroke"},{"issue":"1","key":"zoi240417r9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/CPJ.0000000000000830","article-title":"Systematic review and meta-analysis of diagnostic agreement in suspected TIA.","volume":"11","author":"Lee","year":"2021","journal-title":"Neurol Clin Pract"},{"issue":"27","key":"zoi240417r10","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA.","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"key":"zoi240417r11","doi-asserted-by":"publisher","first-page":"l2211","DOI":"10.1136\/bmj.l2211","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial.","volume":"365","author":"Wang","year":"2019","journal-title":"BMJ"},{"issue":"11","key":"zoi240417r13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi240417r15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zoi240417r16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12874-019-0829-2","article-title":"BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses.","volume":"19","author":"B\u00e9liveau","year":"2019","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"zoi240417r17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaneurol.2021.4514","article-title":"Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.","volume":"79","author":"Lun","year":"2022","journal-title":"JAMA Neurol"},{"issue":"3","key":"zoi240417r18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/jrsm.v7.3","article-title":"GetReal in network meta-analysis: a review of the methodology.","volume":"7","author":"Efthimiou","year":"2016","journal-title":"Res Synth Methods"},{"key":"zoi240417r20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jclinepi.2019.03.007","article-title":"The number needed to treat in pairwise and network meta-analysis and its graphical representation.","volume":"111","author":"Veroniki","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"22","key":"zoi240417r21","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.jcin.2022.08.009","article-title":"P2Y12 inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention: a network meta-analysis.","volume":"15","author":"And\u00f2","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"zoi240417r22","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","article-title":"Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.","volume":"6","author":"Kennedy","year":"2007","journal-title":"Lancet Neurol"},{"issue":"1","key":"zoi240417r23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.v75.1","article-title":"Diffusion-weighted imaging and diagnosis of transient ischemic attack.","volume":"75","author":"Brazzelli","year":"2014","journal-title":"Ann Neurol"},{"key":"zoi240417r12","first-page":"285","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.3","author":"Chaimani","year":"2023"},{"key":"zoi240417r14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/9781119536604.ch8","volume-title":"Cochrane Handbook For Systematic Reviews of Interventions Version 6.0","author":"Higgins","year":"2019"},{"key":"zoi240417r19","unstructured":"Dias? S, Welton? NJ, Sutton? AJ, Caldwell? DM, Lu? G, Ades? A. NICE DSU Technical support document 4: inconsistency in networks of evidence based on randomised controlled trials. University of Sheffield. May 2011. Updated April 2014. Accessed April 8, 2024. https:\/\/www.sheffield.ac.uk\/sites\/default\/files\/2022-02\/TSD4-Inconsistency.final_.15April2014.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2818750\/lim_2024_oi_240417_1715185298.63512.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T15:01:14Z","timestamp":1715871674000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2818750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.11735","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}